Stockscreener 앱 받기
0.00
100.00%
-15.02
시간 외 거래:
14.90
14.90
+
전일 마감가:
$15.02
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.48B
수익:
$11.40B
순이익/손실:
$-95.73M
주가수익비율:
0.00
EPS:
-2.45
순현금흐름:
$-64.37M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(MNMD)의 최신 뉴스
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - Sahm
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
DFTX Should I Buy - Intellectia AI
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics (DFTX) maps late-stage trials in anxiety, depression and autism - Stock Titan
[8-K] Definium Therapeutics, Inc. Reports Material Event | DFTX SEC FilingForm 8-K - Stock Titan
Definium Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga España
Definium Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Wolfe Research - Defense World
Earnings Preview For Definium Therapeutics - Benzinga
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Is It Too Late To Consider Definium Therapeutics (DFTX) After A 158% One Year Surge? - Sahm
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
DFTX: Wolfe Research Initiates Coverage with Outperform Rating | - GuruFocus
Definium Therapeutics to Participate at Upcoming Investor Conferences - The Globe and Mail
Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jefferies assigns 65–75% probability of best-in-class efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - MSN
Avoro Capital Advisors LLC Acquires 5 Million Shares in Definium Therapeutics Inc - GuruFocus
CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - The Joplin Globe
Jefferies’ DT120 Confidence and Psychedelic Tailwinds Might Change The Case For Investing In Definium Therapeutics (DFTX) - Sahm
Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III - Bitget
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - Insider Monkey
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3%Still a Buy? - MarketBeat
Should I buy Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Commodore Capital reports 7.2% Definium Therapeutics (DFTX) ownership stake - Stock Titan
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Roger Adsett Joins The Board - Sahm
What is the current Price Target and Forecast for Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Definium Therapeutics Inc (MNMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):